Skip to main content
icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Technologia·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

icon for Eli Lilly licenses Peptron’s SmartDepot by October 7?
Technologia·Eli Lilly

Eli Lilly licenses Peptron’s SmartDepot by October 7?

13% szansa
Polymarket

$11,138 Wol.

13% szansa
Polymarket

$11,138 Wol.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 Material Transfer Agreement with Peptron grants only a non-exclusive license for internal R&D evaluation of the ultrasonic spray-dried PLGA microsphere SmartDepot platform on select peptides, with any commercial rights explicitly optional. The original 14-month term was extended to a 24-month maximum ending near October 2026, yet nearly 20 months of joint work have produced no technology-transfer, supply, or commercialization deal. Lilly has instead advanced a June 2025 collaboration with Camurus using FluidCrystal technology for long-acting incretins and continues exploring oral obesity candidates. With the evaluation-only structure, alternative partnerships, and limited time remaining before the October 7 resolution date, trader consensus heavily favors “No” at 87.5% implied probability.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Wolumen
$11,138
Data zakończenia
Oct 7, 2026
Rynek otwarty
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s October 2024 Material Transfer Agreement with Peptron grants only a non-exclusive license for internal R&D evaluation of the ultrasonic spray-dried PLGA microsphere SmartDepot platform on select peptides, with any commercial rights explicitly optional. The original 14-month term was extended to a 24-month maximum ending near October 2026, yet nearly 20 months of joint work have produced no technology-transfer, supply, or commercialization deal. Lilly has instead advanced a June 2025 collaboration with Camurus using FluidCrystal technology for long-acting incretins and continues exploring oral obesity candidates. With the evaluation-only structure, alternative partnerships, and limited time remaining before the October 7 resolution date, trader consensus heavily favors “No” at 87.5% implied probability.

This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.

Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.

Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.

The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Wolumen
$11,138
Data zakończenia
Oct 7, 2026
Rynek otwarty
May 5, 2026, 8:02 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”. Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify. Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify. The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.

Powiązane

icon for Will Eli Lilly (LLY) Q2 Zepbound sales be above $4B?

Will Eli Lilly (LLY) Q2 Zepbound sales be above $4B?

93%
icon for Will Eli Lilly (LLY) Q2 Mounjaro sales be above $9B?

Will Eli Lilly (LLY) Q2 Mounjaro sales be above $9B?

80%
icon for Czy FDA zatwierdzi Retatrutide w tym roku?

Czy FDA zatwierdzi Retatrutide w tym roku?

2%
Tak

Uważaj na linki zewnętrzne.

Często zadawane pytania

"Eli Lilly licenses Peptron’s SmartDepot by October 7?" to rynek prognoz na Polymarket, gdzie traderzy kupują i sprzedają udziały "Tak" lub "Nie" w zależności od tego, czy wierzą, że to wydarzenie nastąpi. Obecne zbiorowe prawdopodobieństwo to 13% na "Yes". Na przykład, jeśli "Tak" kosztuje 13¢, rynek zbiorowo przypisuje 13% szansy na to, że to wydarzenie nastąpi. Te kursy zmieniają się ciągle, gdy traderzy reagują na nowe informacje i wydarzenia. Udziały w poprawnym wyniku można wymienić na $1 za sztukę po rozstrzygnięciu rynku.

Na dzień dzisiejszy "Eli Lilly licenses Peptron’s SmartDepot by October 7?" wygenerował $11.1K łącznego wolumenu od uruchomienia rynku May 5, 2026. Ten poziom aktywności handlowej odzwierciedla silne zaangażowanie społeczności Polymarket i pomaga zapewnić, że bieżące kursy są informowane przez głęboką pulę uczestników rynku. Możesz śledzić ruchy cen na żywo i handlować na dowolny wynik bezpośrednio na tej stronie.

Aby handlować na "Eli Lilly licenses Peptron’s SmartDepot by October 7?", wybierz, czy uważasz, że odpowiedź to "Tak" czy "Nie". Każda strona ma bieżącą cenę odzwierciedlającą implikowane prawdopodobieństwo rynku. Wpisz kwotę i kliknij "Handluj". Jeśli kupisz udziały "Tak" i wynik okaże się "Tak", każdy udział wypłaci $1. Jeśli okaże się "Nie", Twoje udziały "Tak" wypłacą $0. Możesz też sprzedać swoje udziały w dowolnym momencie przed rozstrzygnięciem, jeśli chcesz zrealizować zysk lub ograniczyć stratę.

Obecne prawdopodobieństwo dla "Eli Lilly licenses Peptron’s SmartDepot by October 7?" to 13% na "Yes". Oznacza to, że społeczność Polymarket uważa, że istnieje 13% szansy na to, że to wydarzenie nastąpi. Te kursy aktualizują się w czasie rzeczywistym na podstawie rzeczywistych transakcji, dostarczając ciągle aktualizowany sygnał tego, czego rynek oczekuje.

Zasady rozstrzygania "Eli Lilly licenses Peptron’s SmartDepot by October 7?" określają dokładnie, co musi się wydarzyć, aby każdy wynik został ogłoszony zwycięzcą — w tym oficjalne źródła danych używane do ustalenia wyniku. Możesz przejrzeć pełne kryteria rozstrzygania w sekcji "Zasady" na tej stronie nad komentarzami. Zalecamy dokładne zapoznanie się z zasadami przed handlem, ponieważ określają one precyzyjne warunki, przypadki graniczne i źródła regulujące rozstrzyganie tego rynku.